Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer.

Journal for immunotherapy of cancer - 1 Jul 2021

Nam Gi-Hoon, Kwon Minsu, Jung Hanul, Ko Eunbyeol, Kim Seong A, Choi Yoonjeong, Song Su Jeong, Kim Seohyun, Lee Yeji, Kim Gi Beom, Han Jihoon, Woo Jiwan, Cho Yakdol, Jeong Cherlhyun, Park Seung-Yoon, Roberts Thomas M, Cho Yong Beom, Kim In-San

Abstract excerpt

BACKGROUND: Statins preferentially promote tumor-specific apoptosis by depleting isoprenoid such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. However, statins have not yet been approved for clinical cancer treatment due, in part, to poor understanding of molecular determinants on statin sensitivity. Here, we investigated the potential of statins to elicit enhanced immunogenicity of KRAS-mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endoplasmic Reticulum Stress
Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Transfection

Source

Open in PubMed Open full text

Identifiers

PMID: 34330763
DOI: 10.1136/jitc-2021-002474
PMCID: PMC8327837

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer.PMID 34330763Read ↗

Cancer vaccines: Targeting KRAS-driven cancers.Semantic proximity Read ↗

RORγ bridges cancer-driven lipid dysmetabolism and myeloid immunosuppressionSemantic proximity Read ↗

Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells.Semantic proximity Read ↗

Targeting Mevalonate Pathway Enhances the efficacy of 5-Fluorouracil by regulating pyroptosisSemantic proximity Read ↗

The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancerSemantic proximity Read ↗

Statin-dye conjugates for selective targeting of KRAS mutant cancer cells.Semantic proximity Read ↗

In vivo CRISPR screening identifies geranylgeranyl diphosphate as a pancreatic cancer tumor growth dependencySemantic proximity Read ↗

Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models.Semantic proximity Read ↗

Smad7 is a negative regulator of immunogenic cell death in colorectal cancerSemantic proximity Read ↗

The epithelial polarity regulator LGALS9/galectin-9 induces fatal frustrated autophagy in KRAS mutant colon carcinoma that depends on elevated basal autophagic flux.Semantic proximity Read ↗

Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancerSemantic proximity Read ↗

Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.